United States· US:65785-034_445cd72e-831c-98c4-e063-6294a90a7bdc
Eyewash Station Additive Concentrate
A medicinal product containing chlorhexidine gluconate; propylene glycol, registered in United States by Niagara Pharmaceuticals Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CHLORHEXIDINE GLUCONATE; PROPYLENE GLYCOL
- Manufacturer
- Niagara Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1165785-034-01
- ndc116578503401.236 L in 1 BOTTLE, UNIT-DOSE (65785-034-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f85cee37-15f1-4447-9c6c-8b59b2df58dd GET /v1/drugs/f85cee37-15f1-4447-9c6c-8b59b2df58dd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "OPHTHALMIC",
"source": "ndc",
"strength": "145.6; 280",
"substance": "CHLORHEXIDINE GLUCONATE; PROPYLENE GLYCOL",
"productndc": "65785-034",
"dosage_form": "LIQUID",
"dea_schedule": null,
"strength_unit": "kg/2800L; kg/2800L",
"application_number": "M018",
"marketing_category": "OTC MONOGRAPH DRUG"
}See everything about chlorhexidine gluconate; propylene glycol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.